Angela, Yenny <br/><br/>
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases.  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  Jul 2019 
 - 1187-1194 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1432-0851 
<br/><br/><label>Standard No.: </label>10.1007/s00262-019-02353-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Bone Neoplasms--drug therapy<br/>Denosumab--pharmacology<br/>Female<br/>Humans<br/>Ipilimumab--pharmacology<br/>Kaplan-Meier Estimate<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Nivolumab--pharmacology<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Progression-Free Survival<br/>RANK Ligand--antagonists & inhibitors<br/>Retrospective Studies<br/>Skin Neoplasms--drug therapy